low - Rare disease treatments for chronic conditions exhibit minimal correlation to GDP or consumer discretionary spending. LEMS patients require continuous therapy regardless of economic conditions, and insurance/Medicare coverage insulates demand from out-of-pocket cost sensitivity. The 3,000-patient addressable market is clinically defined rather than economically driven.

Rising rates create modest headwinds through higher discount rates applied to future cash flows, compressing valuation multiples for high-margin growth stocks. However, with zero debt and $200M annual FCF generation, Catalyst has no financing cost exposure. The company benefits from higher yields on its substantial cash position (estimated $400M+ given 6.62x current ratio and minimal debt). Rate sensitivity is primarily valuation-driven rather than operational.

growth - The 23.5% revenue growth, 129.5% net income growth, and 106% EPS growth attract growth investors seeking high-margin specialty pharma exposure. However, the 8% FCF yield and potential for capital returns also appeal to value-oriented investors. The orphan drug model with predictable recurring revenue attracts quality-focused long-term holders. Limited institutional ownership in small-cap biotech creates opportunity for fundamental-driven hedge funds.